Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.44 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hygrine SCHEMBL335689 | 1.00 | CHRNB2 (0.44) | CHRNB2CHRNA7CHRNA4CHRNA5CYP1A2 | |
| SCHEMBL14430402 | 0.94 | CYP1A2 (0.48) | CHRNB2CHRNA7CHRNA4CHRNA5CYP1A2 | |
| SCHEMBL21462061 | 0.94 | CYP1A2 (0.48) | CHRNB2CHRNA7CHRNA4CHRNA5CYP1A2 | |
| SCHEMBL30924430 | 0.88 | CHRNB2 (0.38) | CHRNB2CHRNA7CHRNA4CHRNA5CYP1A2 | |
| SCHEMBL14430400 | 0.87 | — | — | |
| SCHEMBL336170 | 0.85 | CHRNB2 (0.45) | CHRNB2CHRNA7CHRNA4CHRNA5CYP1A2 | |
| SCHEMBL336171 | 0.85 | CHRNB2 (0.45) | CHRNB2CHRNA7CHRNA4CHRNA5CYP1A2 | |
| SCHEMBL8198672 | 0.83 | CHRNB2 (0.47) | CHRNB2CHRNA7CHRNA4CHRNA5CYP1A2 | |
| SCHEMBL13740779 | 0.83 | CHRNB2 (0.47) | CHRNB2CHRNA7CHRNA4CHRNA5CYP1A2 | |
| SCHEMBL14077882 | 0.83 | CHRNB2 (0.47) | CHRNB2CHRNA7CHRNA4CHRNA5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544332-B2 | Lipid vesicle compositions with penetration enhancing agents | DDS RESEARCH INC. (CA) | 2026-02-10 | — | — | US | claimed |
| WO-2025059510-A1 | COCA LEAF EXTRACT FOR NEUROPSYCHIATRIC DISORDERS | MAGDALENA BIOSCIENCES, INC. (US) | 2025-03-20 | — | — | WO | claimed |
| US-20240206523-A1 | Compound of reaction of alkaloid and phenol, atomization liquid, cartomizer and electronic atomizer | ZHANG, QI (CN) | 2024-06-27 | — | — | US | claimed |
| US-20240189231-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS REASEARCH INC. (CA) | 2024-06-13 | — | — | US | claimed |
| US-11801221-B2 | Lipid vesicle compositions with penetration enhancing agents | DDS RESEARCH INC. (CA) | 2023-10-31 | — | — | US | claimed |
| US-20230157954-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS REASEARCH INC. (CA) | 2023-05-25 | — | — | US | claimed |
| US-20220386644-A1 | USES OF COCA LEAF OR VALERIAN ROOT TO REDUCE BITTERNESS IN PLANT-BASED FOODS SUCH AS THOSE CONTAINING UNSWEETENED COCOA | AHARONIAN GREGORY (US) | 2022-12-08 | — | — | US | claimed |
| US-20220313606-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS RESEARCH INC. (CA) | 2022-10-06 | — | — | US | claimed |
| EP-4034087-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS Research Inc. (CA) | 2022-08-03 | — | — | EP | claimed |
| US-20220218611-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | DDS RESEARCH INC. (CA) | 2022-07-14 | — | — | US | claimed |
| US-20160021906-A1 | USES OF COCA LEAF OR VALERIAN ROOT TO REDUCE BITTERNESS IN PLANT-BASED FOODS SUCH AS THOSE CONTAINING UNSWEETENED COCOA | AHARONIAN GREGORY (US) | 2016-01-28 | — | — | US | claimed |
| WO-2016014114-A1 | USE OF COCA LEAF OR VALERIAN ROOT TO REDUCE BITTERNESS IN FOODS CONTAINING UNSWEETENED COCOA | AHARONIAN GREGORY (US) | 2016-01-28 | — | — | WO | claimed |
| CN-105153852-A | Interior wall coating material capable of adjusting humidity | TAICANG SHUNRUCHENG BUILDING MATERIALS CO LTD | 2015-12-16 | — | — | CN | claimed |
| EP-2734514-B1 | USE OF A THIOPHENE COMPOUND AS A MATRIX IN THE SPECIFIC DETECTION, IDENTIFICATION AND/OR QUANTIFICATION OF ALKALOIDS BY MALDI-TOF MASS SPECTROMETRY | UNIV ANGERS (FR) | 2015-07-08 | — | — | EP | claimed |
| WO-2015013679-A1 | USES OF COCA LEAF OR VALERIAN ROOT TO REDUCE BITTERNESS IN FOODS CONTAINING UNSWEETENED CACAO | AHARONIAN GREGORY (US) | 2015-01-29 | — | — | WO | claimed |
| US-20140319331-A1 | NEW USE FOR A COMPOUND AS A MATRIX IN THE SPECIFIC DETECTION, IDENTIFICATION AND/OR QUANTIFICATION OF ALKALOIDS BY MALDI-TOF MASS SPECTROMETRY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS (FR) | 2014-10-30 | — | — | US | claimed |
| CN-102174313-B | Low-conductivity super-long-acting organic base type anti-freezing cooling liquid | ADVANCED MFT TECH CT CN CAMST | 2014-01-15 | — | — | CN | claimed |
| CN-102174313-A | Low-conductivity super-long-acting organic base type anti-freezing cooling liquid | ADVANCED MFT TECH CT CN CAMST | 2011-09-07 | — | — | CN | claimed |
| EP-2001877-A1 | METHOD FOR EXTRACTING TARGET ALKALOID USING AN IONIC LIQUID AS EXTRACTING SOLVENT | Bioniqs Limited (GB) | 2008-12-17 | — | — | EP | claimed |
| WO-2007110637-A1 | METHOD FOR EXTRACTING TARGET ALKALOID USING AN IONIC LIQUID AS EXTRACTING SOLVENT | BIONIQS LIMITED (GB) | 2007-10-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140319331-A1 | NEW USE FOR A COMPOUND AS A MATRIX IN THE SPECIFIC DETECTION, IDENTIFICATION AND/OR QUANTIFICATION OF ALKALOIDS BY MALDI-TOF MASS SPECTROMETRY | CIAPIN1, SRMS, MMP7 | CHRNB2 1200/4885CHRNA7 959/4885CHRNA4 1485/4885 |
| US-20240189231-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | LIPA, HDLBP, VAPB | CHRNB2 3206/4885CHRNA7 3843/4885CHRNA4 4066/4885 |
| US-12544332-B2 | Lipid vesicle compositions with penetration enhancing agents | LIPA, CHMP4B, NPC1L1 | CHRNB2 2536/4885CHRNA7 3234/4885CHRNA4 3079/4885 |
| US-11801221-B2 | Lipid vesicle compositions with penetration enhancing agents | LIPA, HDLBP, VAPB | CHRNB2 3206/4885CHRNA7 3843/4885CHRNA4 4066/4885 |
| US-20220313606-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | LIPA, HDLBP, VAPB | CHRNB2 3206/4885CHRNA7 3843/4885CHRNA4 4066/4885 |
| US-20220218611-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | LIPA, HDLBP, VAPB | CHRNB2 3206/4885CHRNA7 3843/4885CHRNA4 4066/4885 |
| US-20230157954-A1 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | LIPA, HDLBP, VAPB | CHRNB2 3206/4885CHRNA7 3843/4885CHRNA4 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.